A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer is a phase 3 interventional study registered as NCT06764485, led by Celgene, and active but no longer recruiting on the registry. Official title: A Phase 3, Two-part, Randomised, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge. Planned enrolment is 960 participants (estimated). The study started in 2025-03-13 and primary completion is expected in 2027-09-12. No results have been posted on ClinicalTrials.gov.